文献速递胃肠动力与功能性疾病

COVID-19后肠易激综合征

Post COVID-19 irritable bowel syndrome.
PubMed 文献 · Gut · 2022-12-09

GI-COVID-19为前瞻性多中心对照研究,纳入2183例住院患者,主分析883例(COVID-19组614例、对照组269例),评估出院后1、6、12个月胃肠道症状及脑-肠轴互动障碍。COVID-19组12个月时便秘和硬便少于对照组,但符合罗马IV标准肠易激综合征的比例高于对照组(0.5%对3.2%,p=0.045)。

要点

  • 住院COVID-19患者12个月时便秘和硬便发生率低于对照组。
  • COVID-19组符合罗马IV标准肠易激综合征的比例为3.2%,对照组为0.5%。
  • 与肠易激综合征诊断相关的因素包括过敏史、长期质子泵抑制剂使用和呼吸困难。

核心结论

  • 与对照组相比,住院COVID-19患者在急性感染后12个月时便秘和硬便问题更少,但肠易激综合征发生率显著更高。

研究设计与样本

  • GI-COVID-19为前瞻性、多中心、对照研究,纳入2183例住院患者,主分析883例(COVID-19组614例、对照组269例),排除既往胃肠道症状和/或手术者,于入院时及出院后1、6、12个月评估。

主要发现

  • 入院时COVID-19组胃肠道症状发生率高于对照组(59.3%对39.7%,p<0.001)。
  • 12个月随访时便秘在对照组为16%、COVID-19组为9.6%(p=0.019),硬便在对照组为17.7%、COVID-19组为10.9%(p=0.011)。
  • 符合罗马IV标准肠易激综合征的比例在COVID-19组为3.2%、对照组为0.5%(p=0.045)。
  • 与肠易激综合征诊断显著相关的因素包括过敏史、长期质子泵抑制剂使用和呼吸困难。
  • 6个月随访时COVID-19组符合抑郁标准的患者比例高于对照组。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The long-term consequences of COVID-19 infection on the gastrointestinal tract remain unclear. Here, we aimed to evaluate the prevalence of gastrointestinal symptoms and post-COVID-19 disorders of gut-brain interaction after hospitalisation for SARS-CoV-2 infection. DESIGN: GI-COVID-19 is a prospective, multicentre, controlled study. Patients with and without COVID-19 diagnosis were evaluated on hospital admission and after 1, 6 and 12 months post hospitalisation. Gastrointestinal symptoms, anxiety and depression were assessed using validated questionnaires. RESULTS: The study included 2183 hospitalised patients. The primary analysis included a total of 883 patients (614 patients with COVID-19 and 269 controls) due to the exclusion of patients with pre-existing gastrointestinal symptoms and/or surgery. At enrolment, gastrointestinal symptoms were more frequent among patients with COVID-19 than in the control group (59.3% vs 39.7%, p<0.001). At the 12-month follow-up, constipation and hard stools were significantly more prevalent in controls than in patients with COVID-19 (16% vs 9.6%, p=0.019 and 17.7% vs 10.9%, p=0.011, respectively). Compared with controls, patients with COVID-19 reported higher rates of irritable bowel syndrome (IBS) according to Rome IV criteria: 0.5% versus 3.2%, p=0.045. Factors significantly associated with IBS diagnosis included history of allergies, chronic intake of proton pump inhibitors and presence of dyspnoea. At the 6-month follow-up, the rate of patients with COVID-19 fulfilling the criteria for depression was higher than among controls. CONCLUSION: Compared with controls, hospitalised patients with COVID-19 had fewer problems of constipation and hard stools at 12 months after acute infection. Patients with COVID-19 had significantly higher rates of IBS than controls. TRIAL REGISTRATION NUMBER: NCT04691895.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Marasco G, Cremon C, Barbaro MR, et al. Post COVID-19 irritable bowel syndrome. Gut. 2022. PMID: 36591612. doi:10.1136/gutjnl-2022-328483

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。